These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1979176)

  • 41. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 46. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
    Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M
    Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.
    Taylor JR; Lawrence MS; Redmond DE; Elsworth JD; Roth RH; Nichols DE; Mailman RB
    Eur J Pharmacol; 1991 Jul; 199(3):389-91. PubMed ID: 1680717
    [No Abstract]   [Full Text] [Related]  

  • 50. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
    Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
    Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
    Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD
    Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
    Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
    Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
    Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
    Fredriksson A; Palomo T; Chase T; Archer T
    J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1993 Jul; 238(2-3):235-40. PubMed ID: 8104807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
    Ogawa N; Mizukawa K; Hirose Y; Kajita S; Ohara S; Watanabe Y
    Eur Neurol; 1987; 26 Suppl 1():16-23. PubMed ID: 2884111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.